Veru Inc.Veru Inc.Veru Inc.

Veru Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪111.76 M‬USD
−0.3440USD
‪−93.15 M‬USD
‪16.30 M‬USD
‪125.73 M‬
Beta (1Y)
−0.66

About Veru Inc.


CEO
Mitchell Shuster Steiner
Headquarters
Miami
Founded
1971
FIGI
BBG000G12J78
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VERU is 0.7337 USD — it has decreased by −2.78% in the past 24 hours. Watch Veru Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Veru Inc. stocks are traded under the ticker VERU.
VERU stock has fallen by −11.45% compared to the previous week, the month change is a −3.25% fall, over the last year Veru Inc. has showed a −25.89% decrease.
We've gathered analysts' opinions on Veru Inc. future price: according to them, VERU price has a max estimate of 5.00 USD and a min estimate of 1.00 USD. Watch VERU chart and read a more detailed Veru Inc. stock forecast: see what analysts think of Veru Inc. and suggest that you do with its stocks.
VERU reached its all-time high on Jan 22, 1992 with the price of 27.0000 USD, and its all-time low was 0.3200 USD and was reached on Dec 29, 2000. View more price dynamics on VERU chart.
See other stocks reaching their highest and lowest prices.
VERU stock is 4.68% volatile and has beta coefficient of −0.66. Track Veru Inc. stock price on the chart and check out the list of the most volatile stocks — is Veru Inc. there?
Today Veru Inc. has the market capitalization of ‪111.76 M‬, it has decreased by −9.31% over the last week.
Yes, you can track Veru Inc. financials in yearly and quarterly reports right on TradingView.
Veru Inc. is going to release the next earnings report on Dec 2, 2024. Keep track of upcoming events with our Earnings Calendar.
VERU earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.06 USD resulting in a −20.69% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Veru Inc. earnings.
Veru Inc. revenue for the last quarter amounts to ‪3.95 M‬ USD, despite the estimated figure of ‪3.50 M‬ USD. In the next quarter, revenue is expected to reach ‪3.56 M‬ USD.
VERU net income for the last quarter is ‪−10.97 M‬ USD, while the quarter before that showed ‪−10.03 M‬ USD of net income which accounts for −9.40% change. Track more Veru Inc. financial stats to get the full picture.
No, VERU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Veru Inc. EBITDA is ‪−41.37 M‬ USD, and current EBITDA margin is −584.99%. See more stats in Veru Inc. financial statements.
Like other stocks, VERU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Veru Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Veru Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Veru Inc. stock shows the sell signal. See more of Veru Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.